Monitoring measurable residual disease and chimerism in patients with JAK2 V617F-positive myelofibrosis after allogeneic hematopoietic cell transplantation

Blood Cancer J. 2023 Jun 26;13(1):97. doi: 10.1038/s41408-023-00867-x.

Jong-Mi Lee^{1

2}, Ari Ahn^{2

3}, Eun Jeong Min⁴, Sung-Eun Lee^#^{5

6}, Myungshin Kim^#^{7

8}, Yonggoo Kim^{1

2}

¹ Department of Laboratory Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
² Catholic Genetic Laboratory Center, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
³ Department of Laboratory Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
⁴ Department of Medical Life Sciences, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
⁵ Department of Hematology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. lee86@catholic.ac.kr.
⁶ Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. lee86@catholic.ac.kr.
⁷ Department of Laboratory Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. microkim@catholic.ac.kr.
⁸ Catholic Genetic Laboratory Center, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. microkim@catholic.ac.kr.

^# Contributed equally.

No abstract available

Publication types